AIM
AIM ImmunoTech Inc.
$0.28
-0.02 (-6.67%)
At close · Jul 2
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed May 15, 2026
Market Cap
$4.08M
Shares
14,563,515
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.28
Open$0.30
Day$0.28–0.31
52W$0.21–19.74
Avg vol 30d39.6M
Short int3.2M · 22.0% float · 1.0d
Short vol56%
Last earningsMay 19, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Strong Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−76% below
−
Price vs 50-day avg
−34% below
◦
RSI (14)
38 · neutral
−
MACD trend
negative
−
52-week position
0% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $0 › 200d $1 — 200d above 50d
+
Institutional flow
+38% holders QoQ · +8 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
22.00% of float · ▼ -54.3% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
18 holders — near 1-yr high, broad support
Fundamentals
Weak
−
Revenue growth
−48% Y/Y
+
EPS growth
+72% Y/Y
−
Free cash flow
$-11.0M
◦
Balance sheet
net debt $1.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−76% below
Bearish
Price vs 50-day avg
−34% below
Bearish
RSI (14)
38 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
0% · near low
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+38% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
22.00% of float · ▼ -54.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
18 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $20
vs 200-day avg -76%
vs 50-day avg -34%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AIM
this stock
AIM ImmunoTech Inc.
|
$4.08M | -74.5% | -48.2% | — | 22.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AIM | -22.2% | -61.6% | -78.5% | +0.0% | -74.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -23.7% | -60.4% | -86.5% | +0.3% | -83.7% |